The AIMS Clinic Model: A Retrospective Analysis of Interdisciplinary Neuropalliative Care for People with Advanced Parkinsonism
Objective: To describe and evaluate the Advanced Interdisciplinary Movement Disorders Supportive Care (AIMS) Clinic, a novel interdisciplinary clinic for patients with advanced movement disorders. Background:…SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor
Objective: KINETIC2 is a multicenter, randomized, placebo-controlled, dose-response Ph2b study evaluating SAGE-324/BIIB124 for treatment of essential tremor (ET). Background: ET is a common movement disorder1,2…A Randomized, Double-blind, Phase 2a Clinical Trial to Study the Efficacy and Safety of Lamotrigine for Treatment of Patients with Dementia with Lewy Bodies
Objective: This proof-of-concept clinical trial will test the efficacy and safety of lamotrigine compared to placebo in patients with dementia with Lewy bodies (DLB). Background:…A Prospective, Multicenter, Single-Arm Feasibility Study Examining ECAP-Controlled, Closed-Loop Spinal Cord Stimulation for Parkinson’s Disease (eCAP-PD): Technical and Design Considerations
Objective: Conduct a prospective feasibility study to determine the effects of ECAP-controlled closed-loop spinal cord stimulation (SCS) on motor symptoms in Parkinson’s disease (PD) patients.…Pharmacological neuromodulation with intracerebroventricular administration of anaerobic dopamine for Parkinson’s disease
Objective: To assess the continuous intracerebroventricular (i.c.v.) of A-dopamine in patients with a telemetry-controlled intra-abdominal pump system connected to a subcutaneous catheter implanted through the…24 Hour Maxillofacial Administration of Levodopa in a Parkinsons Patient -An Alternative Route of Administration in Parkinsons Disease
Objective: To assess tolerability, feasibility, safety and to assess outcome measures clinically as well as by serum levels over 24 hours, using the alternative maxillofacial…Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium
Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins
Objective: To evaluate the incorporation of prognostic digital twins to enhance traditional clinical trials in Parkinson’s Disease (PD) for disease modifying therapies. We assess the…Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder
Objective: To compare the proportion of people with abnormal alpha-synuclein among groups with differing levels of certainty of REM sleep behavior disorder (RBD). Background: REM…Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-Term Data from the Ongoing InfusON Extension Study
Objective: Evaluate outcomes (up to 3 years) from the ongoing Extension Period of the InfusON study (NCT02339064) of continuous subcutaneous apomorphine infusion (CSAI). Background: Primary…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 181
- Next Page »